NYSE:CRY

Stock Analysis Report

Executive Summary

CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide.

Snowflake

Fundamentals

Reasonable growth potential and overvalued.


Similar Companies

Share Price & News

How has CryoLife's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.2%

NYSE:CRY

-0.08%

US Medical Equipment

0.2%

US Market


1 Year Return

-20.0%

NYSE:CRY

14.1%

US Medical Equipment

-0.7%

US Market

CRY underperformed the Medical Equipment industry which returned 14.7% over the past year.

CRY underperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

CRYIndustryMarket
7 Day0.2%-0.08%0.2%
30 Day-13.0%0.5%-2.7%
90 Day-9.6%10.2%1.6%
1 Year-20.0%-20.0%15.0%14.1%1.6%-0.7%
3 Year68.4%68.4%68.4%63.2%40.0%30.9%
5 Year163.3%158.8%131.5%104.9%53.8%36.8%

Price Volatility Vs. Market

How volatile is CryoLife's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CryoLife undervalued based on future cash flows and its price relative to the stock market?

291.39x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

CryoLife's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

CryoLife's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

CryoLife is overvalued based on earnings compared to the US Medical Equipment industry average.

CryoLife is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

CryoLife is poor value based on expected growth next year.


Price Based on Value of Assets

CryoLife is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is CryoLife expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

59.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CryoLife's revenue is expected to grow by 8.4% yearly, however this is not considered high growth (20% yearly).

CryoLife's earnings are expected to grow significantly at over 20% yearly.

CryoLife's revenue growth is expected to exceed the United States of America market average.

CryoLife's earnings growth is expected to exceed the United States of America market average.

CryoLife's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if CryoLife will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has CryoLife performed over the past 5 years?

-35.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CryoLife's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

CryoLife has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

CryoLife has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

CryoLife has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

CryoLife used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

CryoLife's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is CryoLife's financial position?


Financial Position Analysis

CryoLife is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CryoLife's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

CryoLife's level of debt (76.6%) compared to net worth is high (greater than 40%).

Unable to establish if CryoLife's debt level has increased without past 5-year debt data.

Debt is not well covered by operating cash flow (9.6%, less than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 1.1x annual interest expense, ideally 3x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.9x debt.


Next Steps

Dividend

What is CryoLife's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CryoLife's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CryoLife's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CryoLife has not reported any payouts.

Unable to verify if CryoLife's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CryoLife has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CryoLife's salary, the management and board of directors tenure and is there insider trading?

4.9yrs

Average management tenure


CEO

Pat MacKin (52yo)

4.9yrs

Tenure

US$3,231,170

Compensation

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of CryoLife Inc. since September 02, 2014 and has been its Chairman since April 9, 2015 and Director since Oc ...


CEO Compensation Analysis

Pat's remuneration is about average for companies of similar size in United States of America.

Pat's compensation has increased in line with CryoLife recently becoming profitable.


Management Age and Tenure

4.9yrs

Average Tenure

52yo

Average Age

The tenure for the CryoLife management team is about average.


Board Age and Tenure

7.3yrs

Average Tenure

62yo

Average Age

The tenure for the CryoLife board of directors is about average.


Insider Trading

CryoLife individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$57,10003 Jun 19
Scott Capps
EntityIndividual
Role
Other Key Executive
Vice President of Clinical Research
Shares2,000
Max PriceUS$28.55
SellUS$44,49929 May 19
Ronald McCall
EntityIndividual
Role
Lead Director
Presiding Director
Shares1,563
Max PriceUS$28.47
SellUS$106,34624 May 19
Ronald McCall
EntityIndividual
Role
Lead Director
Presiding Director
Shares3,700
Max PriceUS$29.02
SellUS$1,565,69007 May 19
James MacKin
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares50,000
Max PriceUS$31.31
SellUS$269,49407 May 19
David Lee
EntityIndividual
Role
Chief Financial Officer
Executive VP
Shares8,589
Max PriceUS$31.38
SellUS$181,39026 Feb 19
Ronald McCall
EntityIndividual
Role
Lead Director
Presiding Director
Shares6,200
Max PriceUS$29.26
SellUS$172,67206 Sep 18
Ronald Elkins
EntityIndividual
Shares5,000
Max PriceUS$34.53

Ownership Breakdown


Management Team

  • David Lee (54yo)

    Executive VP

    • Tenure: 19.3yrs
    • Compensation: US$1.26m
  • Amy Horton (49yo)

    VP & Chief Accounting Officer

    • Tenure: 13.0yrs
  • Pat MacKin (52yo)

    Chairman

    • Tenure: 4.9yrs
    • Compensation: US$3.23m
  • Scott Capps (52yo)

    Vice President of Clinical Research

    • Tenure: 11.8yrs
    • Compensation: US$646.00k
  • Jean Holloway (62yo)

    Senior VP

    • Tenure: 4.3yrs
    • Compensation: US$1.03m
  • John Davis (54yo)

    Senior Vice President of Global Sales & Marketing

    • Tenure: 3.9yrs
    • Compensation: US$923.37k
  • Karen Dabbs

    Assistant Corporate Secretary

    • Tenure: 0.0yrs
  • Mike Simpson (51yo)

    Senior Vice President of Regulatory Affairs & Quality Assurance

    • Tenure: 0.7yrs

Board Members

  • Ronald McCall (82yo)

    Presiding Director

    • Tenure: 13.7yrs
    • Compensation: US$192.91k
  • Jim Bullock (62yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$176.87k
  • Thomas Ackerman (64yo)

    Director

    • Tenure: 15.7yrs
    • Compensation: US$183.33k
  • Dan Bevevino (59yo)

    Director

    • Tenure: 15.7yrs
    • Compensation: US$189.79k
  • Harvey Morgan (77yo)

    Director

    • Tenure: 11.3yrs
    • Compensation: US$190.31k
  • Jeff Burbank (56yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$172.39k
  • Jon Salveson (54yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$181.35k
  • Pat MacKin (52yo)

    Chairman

    • Tenure: 4.9yrs
    • Compensation: US$3.23m
  • Marna Borgstrom (65yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$139.57k

Company Information

CryoLife, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CryoLife, Inc.
  • Ticker: CRY
  • Exchange: NYSE
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$980.885m
  • Shares outstanding: 37.50m
  • Website: https://www.cryolife.com

Number of Employees


Location

  • CryoLife, Inc.
  • 1655 Roberts Boulevard NW
  • Kennesaw
  • Georgia
  • 30144
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRYNYSE (New York Stock Exchange)YesCommon StockUSUSDFeb 1993
CYLDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1993

Biography

CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company opera ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 23:38
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.